GSK has reported topline results from a phase 3 trial of its novel antibiotic gepotidacin that could spell the end of a decades-long drought in new oral therapies for gonorrhoea. In the EAGLE-1 ...

GSK’s follow-up to its severe asthma therapy Nucala has shown its value in a pair of phase 3 trials, reducing exacerbations compared to placebo with dosing once every six months. The company ...

Faye is the Chief Content Officer of Galvanized Brands, overseeing all editorial content for Eat This, Not ... We offer the most up-to-date information from top experts, new research, and health ...

Jefferies projects a peak opportunity of at least $3 billion for DYNE-101 ... according to Jefferies. GSK to Stay Out of Obesity—but not GLP-1s At JPM25 on Monday, GSK Chief Scientific Officer Tony ...

Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

GSK expects 2025 sales growth between 3% and 5%, with core operating profit and EPS growth projected at 6% to 8%. Specialty medicines are anticipated to lead growth, with low double-digit ...

GSK said it expects core operating profits to rise by between 6% and 8% this year, with turnover set to lift by between 3% and 5%. It added that it expects further growth to be boosted by its ...

GSK said it now e American depositary shares of GSK jumped more than 8% Wednesday after the drugmaker reported better-than-expected quarterly results and boosted its long-term sales forecast.

GSK (GSK), a large British drug maker, is rallying 8% after reporting higher-than-expected fourth-quarter earnings per share and raising its long-term revenue guidance. Last quarter, its operating ...

Harvey Jones has something to celebrate after a positive set of results boosted the GSK share price after a disappointing ... solid but not spectacular at 3.9%.Glaxo’s full-year 2024 dividend ...

Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. GSK does not need a miracle cure — just some rest and rehabilitation. Investors, though, seem unwilling ...